A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
Year: 2018
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Gynecologic Oncology
Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Roswell Park Comprehensive Cancer Center, NRG Oncology, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Cancer Research for the Ozarks, Maine Medical Center, Maine Medical Center, University of Oklahoma Health Sciences Center, University of Iowa Hospitals and Clinics, Levine Cancer Institute
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1291646684, Washington University/ Siteman Cancer Center Lead Academic Site, G1950154987, G2244966566, G2304223924, G289723095, G4054617085, NRG Oncology Network Group Operations Center, G434901823, G5996839100, G6062084349, Lead Academic Participating Site for the Development and Conduct of NCTN Trials, G8494369300, Clinical and Translational Science Collaborative of Cleveland, Cancer Center Support Grant, NRG Oncology - Statistical and Data Management Center
OpenAlex ID: W2906473874